BRANDON LUNSFORD: Open Payments
NPI 1154085819 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$854 in 45 payments from 10 companies in 2025. Trend: 2023 $787 · 2024 $800 · 2025 $854
Food & beverage: $854
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $434 |
| Lilly USA, LLC | 2 | $146 |
| AstraZeneca Pharmaceuticals LP | 3 | $76 |
| Insulet Corporation | 2 | $42 |
| SANOFI-AVENTIS U.S. LLC | 2 | $39 |
| Amgen Inc. | 2 | $38 |
| Globus Medical, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
Products named: VRAYLAR, JARDIANCE, UBRELVY, QULIPTA, FARXIGA, Omnipod, TZIELD, Senza.
Industry payments across TX — which companies pay providers there.
